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Abstract 
Congenital Diaphragmatic Hernia (CDH) is surgically correctable, yet the poor lung 
development determines mortality and morbidity. In isolated cases the outcome can 
be predicted prenatally by medical imaging. Cases with a poor prognosis could be 
treated before birth. Prenatal modulation of lung development however remains 
experimental. Fetoscopic Endoluminal Tracheal Occlusion triggers lung growth and is 
currently being evaluated in a global clinical trial (www.totaltrial.eu). Prenatal 
transplacental sildenafil administration may in due course be a therapeutic approach, 
reducing the occurrence of persistent pulmonary hypertension, either alone or in 
combination with fetal surgery.  
 
Keywords: congenital diaphragmatic hernia – prenatal therapy - pulmonary 
hypoplasia -   pulmonary hypertension - sildenafil 
Introduction 
Congenital diaphragmatic hernia (CDH) occurs in approximately 1 in 2500 births and 
therefore, in the EU-27, approximately 2,100 babies with are born annually. The defect 
typically is left sided in 85% (LCDH), yet 13% are right sided (RCDH), while the 
reminder minority is bilateral or there is complete agenesis [1, 2]. From the embryonic 
phase, abdominal organs herniate through the defect interfering with lung growth, 
resulting in developmental arrest of both airways and vasculature. Hypoplastic lungs 
have fewer and less mature airway branches and impaired vascular development, 
including a smaller cross-sectional area of pulmonary vessels, structural vascular 
remodeling and altered vasoreactivity [3]. At birth, this results in respiratory 
insufficiency and persistent pulmonary hypertension (PHT), which cannot be solved 
simply by the surgical repair of the diaphragm. Despite improved and more 
standardized neonatal management, overall survival of neonates with CDH remains at 
around 70% [4]. PHT is a major cause of neonatal death and morbidity.  
 
Antenatal assessment.  
Prenatal ultrasound identifies two out of three cases of CDH [5], providing the 
opportunity for in utero referral to a tertiary care center for expert assessment and 
perinatal management. Additional genetic and morphologic assessment using 
ultrasound or magnetic resonance imaging can be used to rule out associated 
malformations [6]. For isolated cases clinicians can individualize prognosis to counsel 
parents about prenatal options. A detailed description of potential prognostic indices 
goes beyond the purpose of this review. Briefly, most of the prediction methods are 
based on lung size, liver herniation and pulmonary circulation, and more recently 
stomach position [7-12]. Ultrasound measurement of the lung-to-head-ratio (LHR) is 
most widely practiced. It involves a standardized 2D-ultrasound measurement of the 
lung contralateral to the defect at the level of the four chamber view of the heart. The 
observed LHR is expressed as a proportion of what is expected in a normal fetus of 
the same gestational age (o/eLHR), allowing prediction of prognosis independently of 
gestational age [7, 13]. The combination of liver herniation and o/eLHR is currently 
used by prenatal management centers to stratify fetuses with LCDH and RCDH into 
groups with different increasing pulmonary hypoplasia and corresponding mortality 
rates (Figure 1). Those with the worst prognosis may be offered intrauterine treatment.  
Severity assessment by Magnetic Resonance Imaging (MRI) theoretically has several 
advantages over ultrasound. Visualization is not limited by maternal habitus, amniotic 
fluid volume or fetal position. Furthermore, MRI volumetric measurement of both lungs 
may better predict postnatal lung function. Volumetry may also accurately quantify liver 
and stomach herniation [14, 15]. Though one may claim that lung volume and liver 
herniation MR better predict outcome than ultrasound [16], in clinical practice, it may 
be difficult to prove [17].  
Lung size and liver herniation also predict neonatal morbidity, such as the duration of 
assisted ventilation, the need for supplemental oxygen, the need for patch repair and 
the time it takes to full enteral feeding [18, 19]. The literature on prediction of PHT is 
more limited (systematically reviewed in [20]). Several candidate parameters have 
been suggested in single case series, including lung size, presence of visceral 
herniation, and also direct assessment of the pulmonary vasculature, which may 
provide additional information.    
 
Fetal Therapy for CDH today 
The ability to identify a future non-survivor prenatally prompts the quest for a prenatal 
intervention that can improve outcome. In fetuses with poor prognosis, fetal lung 
growth can be stimulated by fetoscopic endoluminal tracheal occlusion (FETO) with a 
balloon [9, 21-23]. The concept “plug the lung until it grows” is inspired by clinical 
observations in fetuses with laryngeal atresia who have a marked increased lung 
volume and alveolar number. Airway obstruction prevents egress of pulmonary fluid 
which experimentally has been shown to prompt lung growth by a mechanism of 
stretch of lung parenchymal cells [24]. Those experimental findings have been clinically 
translated into a percutaneous procedure without serious maternal morbidity (Figure 
2).  
Technique for balloon insertion.  
We perform FETO under local anesthesia and sono-endoscopic guidance. First the 
fetal and placental position are determined for optimal trocar insertion. When 
necessary, the fetus is externally manipulated to enable a safe and effective access to 
the mouth. A neuromuscular blocking agent, fentanyl and atropine are administered to 
the fetus for immobilization, anesthesia, and prevention of fetal bradycardia 
respectively. A disposable, thin-walled flexible cannula loaded with a pyramidal trocar 
or using the Seldinger technique, is inserted through the skin and myometrium avoiding 
the placenta. Under ultrasound guidance the cannula is targeted to or above the fetal 
nose tip. Fetoscopic instruments specifically designed for FETO include a slightly bent 
3.3 mm sheath loaded with a fiber optic endoscope (1.3 mm; Karl Storz) and the 
balloon occlusion system (catheter loaded with a detachable inflatable latex balloon 
with integrated one-way valve Goldbal 2, Balt Extrusion, France). This balloon can 
accommodate an increasing diameter as the fetal trachea grows during pregnancy. It 
appears on ultrasound examination as a fluid-filled structure. Through the sheath we 
also pass a stylet and/or forceps to remove the balloon if wrongly positioned. Irrigation 
for clearing the operative field and improving visualization can be connected to the side 
port. Fetoscopic landmarks are the philtrum and upper lip, the tongue and raphe of the 
palate, uvula, epiglottis, and eventually the vocal cords. The endoscope is advanced 
into the trachea until identification of the carina, above which the balloon is positioned 
by inflation and detachment from the catheter. The median duration of FETO is 10 
(range, 3–93) minutes, dependent on both the experience of the operator and the 
position of the fetus [25]. A longer operation time is the main risk factor for membrane 
rupture.  
Technique for balloon removal  
Experimental data suggest benefit of temporary tracheal occlusion (“plug-unplug” 
sequence) by stimulating lung maturation [26, 27], which prompted clinicians to attempt 
timely in utero reversal as much as possible. Also clinical data suggest that prenatal 
balloon removal increases neonatal survival [21] and reduces neonatal morbidity [8]. 
Leaving the tracheal occlusion until delivery may provide additional lung growth and 
theoretically avoid the risk for preterm delivery from the second fetoscopic intervention 
of balloon removal [23, 28]. Conversely, it may lead to more emergency removals at 
the time of birth which are challenging and risky [29].  
  
We therefore schedule elective intrauterine occlusion reversal at 34 weeks in patients 
with an uneventful post-operative course. We have used ultrasound-guided puncture, 
fetoscopic removal, tracheoscopic removal on placental circulation and postnatal 
puncture. Ultrasound-guided in utero balloon puncture is done after fetal immobilization 
and fetal analgesia. The lung fluid which is at high pressure under the occlusion pushes 
the punctured balloon into the pharynx, from where it is either swallowed or falls into 
the amniotic cavity. Tracheal patency may be confirmed by a change in tracheal 
diameter and flushing under ultrasound Power Doppler examination. Fetoscopic 
removal is done with similar instruments as for insertion. Initially we used a forceps 
(11510C Karl Storz) only, yet fetoscopic puncture with a stylet (11506P Karl Storz) 
dramatically reduced the operation time. The forceps is still used to grasp the tail of 
the balloon and retrieve it [29].  
In 20% of cases, patients present earlier than planned with threatened preterm 
delivery, with or without ruptured membranes. Whenever clinically possible, we try to 
remove the balloon in utero, using the same techniques. This will be delayed as long 
as possible and may need to be done in an emergency. If considered not possible or 
safe, removal will be done at delivery. We have performed in utero balloon removal in 
the presence of ruptured membranes, in early labour or with early signs of chorio-
amnionitis. If in utero retrieval does not seem safe or possible, we remove the balloon 
by laryngo-tracheoscopy during a modified cesarean section under loco-regional 
anesthesia, with the fetal head and shoulders delivered, while the fetus remains on 
placental circulation (Figure 3A) [30]. Post-delivery removal is a last resort, which we 
do by video laryngo-tracheoscopy, although blind or ultrasound-guided ex utero 
puncture have also been reported [31].  
We recently reported outcomes on 302 balloon insertions at three FETO-centers [29]. 
Balloon removal was elective in 72% of cases and as an emergency in 28%. The 
primary method was by fetoscopy in the majority of cases (67%), by ultrasound 
guidance in 21%, by tracheoscopy on placental circulation in 10%, and postnatal 
tracheoscopy in 1%. In 3%, a second removal attempt was required. Each surgeon 
had a different preferred primary technique. There was no difference in the interval to 
delivery between fetoscopic and ultrasound-guided removal in elective cases. There 
were nine balloon removals attempted outside the FETO centers. Retrieval was 
impossible in three cases, leading to iatrogenic neonatal death (Figure 3B).   
Outcomes of FETO 
Compared to historical controls of similar severity, FETO increases survival rate from 
24% to 49% in LCDH with o/eLHR<25%, and from 17% to 42% in RCDH with 
o/eLHR<45% [25, 32]. FETO also seems to reduce early neonatal respiratory morbidity 
[8, 19]. This potential benefit is now being investigated in two parallel randomized 
clinical trials (RCT) “Tracheal Occlusion To Accelerate Lung growth” 
(www.TOTALtrial.eu), in fetuses with LCDH and severe or moderate lung hypoplasia 
(NCT01240057 and NCT00763737) [33]. Current participating fetal therapy centers 
are from Europe (Leuven, Belgium; Paris, France; London, United Kingdom; 
Barcelona, Spain; Milano & Rome, Italy; Bonn, Germany); from Toronto, Canada; 
Brisbane, Australia and most recently Houston, Texas. The second interim analysis 
(n= 147) of the moderate trial did not identify safety issues. With an increase in 
recruitment, as additional centers from the United States and Japan will join, it is hoped 
to finish the moderate lung hypoplasia trial within 2-3 years. The trial on severe lung 
hypoplasia cases has reached recruitment for the first interim analysis time point.  
Whatever the outcome of the TOTAL-trial, FETO is invasive and has an increased risk 
for preterm delivery, partly offsetting the beneficial effects of fetal therapy. In our pre-
trial experience (>200 cases), preterm rupture of membranes <34 weeks occurred in 
25% of patients. Delivery took place at a median of 35 weeks, but 30% delivered before 
34 weeks, requiring urgent balloon retrieval. Gestational age at delivery logically is an 
important predictor of survival and morbidity in CDH fetuses, also when undergoing 
fetal therapy [8] (Figure 4). Based on our available data, TO does lead to tracheal 
widening, yet without impact on survival or the requirement for early respiratory support 
[34-36]. 
The logistics and skills for FETO are not a given, therefore FETO is difficult to widely 
implement. Finally, the maximum post-FETO survival reported in severe cases is 50-
60%, which in part is caused by insufficient airway growth and, above all, limited 
improvement of vascular development. Indeed, while FETO increases lung size, it 
does not seem to solve the problem of PHT. Alternative prenatal strategies are 
therefore required, ideally also addressing the problem of PHT and preferentially 
medical rather than surgical, to overcome the risks and limitations of fetal procedures. 
Non-surgical experimental antenatal solutions 
We, as well as others, are therefore exploring transplacental pharmacologic 
modulation of lung development. We have focused on methods also affecting vascular 
development. Though new ventilation strategies and medical treatments may have 
improved the outcome of infants with respiratory insufficiency, there is no post-natal 
therapy with proven efficacy for CDH-related PHT. PHT has become the major cause 
of mortality and morbidity in CDH [37]. Infants with CDH, unlike for other causes of 
neonatal respiratory failure, often present with PHT refractory to inhaled nitric oxide 
(NO) [38]. The presence and severity of PHT predicts pulmonary morbidity and death 
[39, 40]. Beyond PHT in the neonatal period, newly emerging patterns of late (months 
after birth) and chronic (years after birth) PHT also affect the long-term quality of life in 
CDH survivors [41]. PHT is also a serious economic burden. Postnatal management 
costs of a CDH-newborn are higher when PHT is present, mainly due to the increased 
use of extra-corporeal membrane oxygenation [42]. To this, the burden of chronic PHT 
must be added. Chronic PHT is associated with an increased risk of death, cardiac 
and pulmonary complications and re-hospitalization, and requires chronic medical 
treatment and follow-up [43]. For all these reasons, an effective strategy to treat or 
prevent PHT would be welcomed. As for airway development, this ideally would 
already start in utero, in order to prevent the structural changes that lead to PHT after 
birth.  
The best candidate would be a treatment for PHT already proven safe and effective 
postnatally. Ideally the drug should be effective after maternal intake, and should have 
no significant adverse effects on the mother or fetus. This strategy would also allow a 
wider implementation than fetal surgery, including in low-income countries. Such an 
approach would be the first universally affordable therapy for CDH ever. 
Sildenafil  
Sildenafil is a selective and potent inhibitor of phosphodiesterase 5 (PDE5), which 
specifically degrades cyclic guanosine monophosphate (cGMP). It is found in high 
concentrations in pulmonary arteries and the corpora cavernosa. PDE5 is abundantly 
expressed during fetal life, where it acts as a key regulator of the perinatal pulmonary 
circulation [44]. Experimental studies on chronic PHT in newborn animals have 
demonstrated impaired endothelial release of NO and increased production of 
vasoconstrictors [45]. Increased PDE5 activity may contribute to this phenomenon [46].  
The mechanism of action of sildenafil on the pulmonary vasculature is depicted in 
Figure 5. Apart from having a vasodilatory effect, sildenafil promotes pulmonary 
angiogenesis and inhibits pulmonary artery remodelling [47]. These properties make 
sildenafil a potential candidate to prevent the vascular changes leading to PHT in CDH 
newborns.  
Sildenafil is approved by the European Medical Agency and the Food & Drug Agency 
for use in PHT in adults [48]. It is also effective and well tolerated in children affected 
by PHT, as shown in the STARTS RCTs [49, 50]. There is a growing interest for the 
use of sildenafil in the newborn for the treatment of PHT of various etiologies [51], 
including CDH [52]. Sildenafil has also already been widely used in pregnant women. 
There were initial case reports on its chronic use in mothers with PHT, showing 
maternal improvement without apparent side effects on the fetus [53-55]. Sildenafil has 
also been evaluated in two small case series for the treatment of early onset 
preeclampsia [56] and intrauterine growth restriction (IUGR) [57], and one RCT in 
pregnancies complicated by idiopathic oligohydramnios [58]. No fetal, neonatal or 
maternal side effects have yet been shown. Finally, there are to our knowledge 
currently four ongoing phase III trials with sildenafil treatment during pregnancy, three 
for severe early onset IUGR [59] and one in normal pregnancies to evaluate safety to 
reduce intrapartum fetal compromise [60]. All this suggests that sildenafil is a 
reasonable option to be evaluated in clinical trials with CDH cases from mid-gestation 
onwards.  
Thébaud was the first to show the benefit of transplacental sildenafil in CDH using the 
nitrofen induced model of CDH [61]. Sildenafil was administered subcutaneously to the 
dams from E11.5 to E20.5 (term=21d) and was detected in fetal blood. It induced a 
marked increase in lung cGMP in CDH fetuses, and a significant attenuation in active 
PDE5 expression, indicating biological activity in the fetal lung. Sildenafil improved lung 
structure, increased pulmonary vessel density, reduced right ventricular hypertrophy 
and improved postnatal pulmonary artery relaxation. It had no demonstrable adverse 
effects on the fetal retina and brain, neither adverse maternal effects. Since then, the 
efficacy of antenatal sildenafil in that nitrofen CDH rat-model has been confirmed [62-
65], also when given at a more clinically relevant timing [66].  
In a recent placebo-controlled trial with transplacental sildenafil given to fetal rabbits 
with CDH, we confirmed both the safety and efficacy of the drug (Figure 6) [67]. The 
rabbit model is clinically more relevant than the nitrofen-CDH rodent as it is a larger 
species. We first performed a dose-finding study demonstrating that subcutaneous 
administration of 10 mg/Kg/d sildenafil resulted in therapeutic levels (target 47 ng/mL, 
proven therapeutic in the STARTS-1 trial for PHT in children [49]) for at least 22 h/day. 
There were no differences in maternal weight change, heart rate change, behavior, 
fetal loss rate and fetal body weight in animals treated with sildenafil or placebo. Then 
efficacy was shown in 38 rabbit fetuses with CDH, randomized to either daily placebo 
or sildenafil from gestational day 24 until term (31d). The wall thickness of peripheral 
pulmonary vessels was increased in placebo-exposed CDH-fetuses as compared to 
normal controls, yet fell in the normal range when CDH-fetuses were exposed to 
sildenafil. CDH fetuses had also proportionally more muscularized peripheral vessels 
than control pups, whereas sildenafil treatment was associated with peripheral 
muscularization in the normal range. Three-dimensional blood vessel architecture was 
assessed using micro-CT showing fewer vessels of the fifth order or higher (thus distal) 
in placebo exposed CDH-pups compared to controls. Again, the number of `distal` 
vessels of sildenafil-exposed CDH fetuses was in the normal range. Small diameter 
arteries are the main determinants of pulmonary vascular resistance. An increase in 
their number will reduce resistance. This, combined with a change in their compliance 
and thinner and less muscularized walls, should better accommodate post-natal 
transition and help prevent PHT. We also studied the functional effects of sildenafil, 
i.e. reduced in utero pulmonary vascular resistance evidenced at term by micro-
ultrasound Doppler studies. Besides the effect on vessels, the drug also improved the 
morphology of the airways, and improved postnatal lung mechanics as demonstrated 
by Flexivent-ventilation. In summary, sildenafil-induced changes in the vascular 
compartment were paralleled by changes in airway development. Of interest, sildenafil 
seemed to have a detrimental effect on vascular branching in non-hypoplastic lungs of 
normal rabbit fetuses.  
We later investigated the effect of combining maternal sildenafil and fetal TO, again in 
fetal rabbits with CDH [68]. In line with earlier experiments, fetal TO alone restored 
normal lung size and airway structure, yet did not reverse pathologic changes in 
peripheral pulmonary vessels. Conversely, sildenafil alone reversed these vascular 
abnormalities to normal values, yet also partly rescued airway development, again 
without increasing lung size. CDH fetuses treated with sildenafil and TO had both a 
normal lung vascular structure and normal lung parenchyma and size. These results 
suggest that maternal sildenafil combined with fetal TO have a synergistic effect on 
vascular and parenchymal lung development.  
As a next step to clinical translation, we evaluated transfer of sildenafil through the 
human placenta, by using an ex-vivo placenta perfusion model [69]. Our preliminary 
data demonstrate that sildenafil crosses the placenta at increasing rates according to 
maternal concentration [70]. The relatively high transfer rate, with a feto-maternal 
concentration ratio between 1 and 1.2 at steady state, suggests that there is sufficient 
placental transfer to reach target fetal drug levels at non-toxic maternal doses. All these 
results have prompted us to apply to the European Medical Agency for orphan 
designation of this drug for the prenatal prevention of PHT in CDH.  
 
  
Practice points   
 Patients with an antenatal diagnosis of CDH should receive individualized 
counseling on expected outcome 
 In severe to moderate lung hypoplasia cases, prenatal interventions may be 
considered.  
 FETO is the only fetal treatment currently available, yet it is investigational and 
should be offered within the framework of the TOTAL randomized clinical trial.  
 FETO may fail to induce sufficient parenchymal and vascular lung growth and/or 
may cause prematurity. 
 
Research directions 
 Investigating alternative, preferentially non-surgical, antenatal strategies   
 Defining effective interventions to prevent both respiratory insufficiency and 
PHT  
 Transplacental sildenafil, above all, seems close to clinical application.  
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Captions 
Figure 1: Patient stratification and selection of candidates for intrauterine therapy 
according to the o/e LHR for LCDH (A) and RCDH (B). Adapted from Jani et al [13] 
and DeKoninck et al [32].  
Figure 2: Schematic drawing of percutaneous fetoscopic endoluminal tracheal 
occlusion. Inset: a detachable balloon, normally used for endovascular occlusion, is 
positioned in the trachea. Reproduced with permission from UZ Leuven, Leuven, 
Belgium. Drawing Myrthe Boymans.  
Figure 3: A Schematic drawing of balloon removal on placental circulation by 
laryngeo-tracheoscopy. Reproduced with permission from UZ Leuven, Leuven, 
Belgium. Drawing Myrthe Boymans. B Flow chart of balloon removal technique. 
Numbers are from a multicenter study, with both % of primary attempts and the 
success rate of the technique. Adapted from Jimenez et al [29].   
Figure 4:Survival rate in LCDH cases with o/eLHR <25% after FETO, according to 
gestational age at delivery [71].  
Figure 5: Schematic representation of the mechanism of action of sildenafil on the 
pulmonary vasculature. eNOS: endothelial nitric oxide synthase; NO: nitric oxide; GC: 
guanylate cyclase; GTP: guanosine triphosphate; GMP: guanosine triphosphate;  
cGMP: cyclic GMP; PDE: phosphodiesterase; ATP: adenosine triphosphate; AMP: 
adenosine monophosphate; cAMP: cyclic AMP; PKG: cGMP dependent protein 
kinase; PKA: cAMP dependent protein kinase. Reproduced with permission from UZ 
Leuven, Leuven, Belgium. Drawing Myrthe Boymans. 
Figure 6: Effect of sildenafil on lung vasculature in the CDH rabbit model. (A) 
Representative and Miller’s stained lung sections showing differences in lung in medial 
and adventitial thickness of peripheral vessels in the four study groups. (B) 
Representative 3D surface rendered images showing impaired vascular branching in 
CDH-fetuses, which is restored by exposure to sildenafil. Reproduced, with permission 
from the publisher, and from Russo et al [67]. 
 
